|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 10 (November 15), 1998:
pp. 3793-3803
An In Vivo Topoisomerase II Cleavage Site and a DNase I
Hypersensitive Site Colocalize Near Exon 9 in the MLL
Breakpoint Cluster Region
Pamela L. Strissel,
Reiner Strick,
Janet D. Rowley, and
Nancy
J. Zeleznik-Le
From the Department of Medicine, University of Chicago, Chicago, IL.
The human myeloid-lymphoid leukemia gene, MLL (also called
ALL-1, Htrx, or HRX ), maps to chromosomal band
11q23. MLL is involved in translocations that result in de novo
acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML),
mixed lineage leukemia, and also in therapy AML (t-AML) and therapy ALL
(t-ALL) resulting from treatment with DNA topoisomerase II (topo II)
targeting drugs. MLL can recombine with more than 30 other
chromosomal bands, of which 16 of the partner genes have been cloned.
Breaks in MLL occur in an 8.3-kb breakpoint cluster region
(BCR) encompassing exons 5 through 11. We recently demonstrated that
75% of de novo patient breakpoints in MLL mapped in the
centromeric half of the BCR between two scaffold-associated
regions (SAR), whereas 75% of the t-AML patient breakpoints mapped to
the telomeric half of the BCR within a strong SAR. We have mapped
additional structural elements in the BCR. An in vivo DNA topo II
cleavage site (induced with several different drugs that target topo
II) mapped near exon 9 in three leukemia cell lines. A strong DNase I
hypersensitive site (HS) also mapped near exon 9 in four leukemia cell
lines, including two in which MLL was rearranged [a t(6;11)
and a t(9;11)], and in two lymphoblastoid cell lines with normal
MLL. Two of the leukemia cell lines also showed an in vivo topo
II cleavage site. Our results suggest that the chromatin structure of
the MLL BCR may influence the location of DNA breaks in both de
novo and therapy-related leukemias. We propose that topo II is enriched
in the MLL telomeric SAR and that it cleaves the DNase I HS
site after treatment with topo II inhibitors. These events may be
involved in recombination associated with t-AML/t-ALL breakpoints
mapping in the MLL SAR.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Szekvolgyi, Z. Rakosy, B. L. Balint, E. Kokai, L. Imre, G. Vereb, Z. Bacso, K. Goda, S. Varga, M. Balazs, et al.
Ribonucleoprotein-masked nicks at 50-kbp intervals in the eukaryotic genomic DNA
PNAS,
September 18, 2007;
104(38):
14964 - 14969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Azarova, Y. L. Lyu, C.-P. Lin, Y.-C. Tsai, J. Y.-N. Lau, J. C. Wang, and L. F. Liu
From the Cover: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
PNAS,
June 26, 2007;
104(26):
11014 - 11019.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Mistry, C. A. Felix, R. J. Whitmarsh, A. Mason, A. Reiter, B. Cassinat, A. Parry, C. Walz, J. L. Wiemels, M. R. Segal, et al.
DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia
N. Engl. J. Med.,
April 14, 2005;
352(15):
1529 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard
Insights into Leukemogenesis from Therapy-Related Leukemia
N. Engl. J. Med.,
April 14, 2005;
352(15):
1591 - 1594.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Libura, D. J. Slater, C. A. Felix, and C. Richardson
Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion
Blood,
March 1, 2005;
105(5):
2124 - 2131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Khobta, C. Carlo-Stella, and G. Capranico
Specific Histone Patterns and Acetylase/Deacetylase Activity at the Breakpoint-Cluster Region of the Human MLL Gene
Cancer Res.,
April 15, 2004;
64(8):
2656 - 2662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Greaves, A. T. Maia, J. L. Wiemels, and A. M. Ford
Leukemia in twins: lessons in natural history
Blood,
October 1, 2003;
102(7):
2321 - 2333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Betti, M. J. Villalobos, M. O. Diaz, and A. T. M. Vaughan
Apoptotic Stimuli Initiate MLL-AF9 Translocations that Are Transcribed in Cells Capable of Division
Cancer Res.,
March 15, 2003;
63(6):
1377 - 1381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Tennyson, N. Ebran, A. E. Herrera, and J. E. Lindsley
A Novel Selection System for Chromosome Translocations in Saccharomyces cerevisiae
Genetics,
April 1, 2002;
160(4):
1363 - 1373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang, P. Strissel, R. Strick, J. Chen, G. Nucifora, M. M. Le Beau, R. A. Larson, and J. D. Rowley
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia
PNAS,
February 20, 2002;
(2002)
42702899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stanulla, P. Chhalliyil, J. Wang, S. N. Jani-Sait, and P. D. Aplan
Mechanisms of MLL gene rearrangement: site-specific DNA cleavage within the breakpoint cluster region is independent of chromosomal context
Hum. Mol. Genet.,
October 1, 2001;
10(22):
2481 - 2491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Blanco, T. Dervieux, M. J. Edick, P. K. Mehta, J. E. Rubnitz, S. Shurtleff, S. C. Raimondi, F. G. Behm, C.-H. Pui, and M. V. Relling
Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia
PNAS,
August 28, 2001;
98(18):
10338 - 10343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. F. KRYNETSKAIA, X. CAI, J. L. NITISS, E. Y. KRYNETSKI, and M. V. RELLING
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II
FASEB J,
November 1, 2000;
14(14):
2339 - 2344.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Binaschi, M. E. Borgnetto, and G. Capranico
Loss of drug-stimulated topoisomerase II DNA breaks in living cells is different at two unrelated loci
Nucleic Acids Res.,
September 1, 2000;
28(17):
3289 - 3293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Strissel, R. Strick, R. J. Tomek, B. A. Roe, J. D. Rowley, and N. J. Zeleznik-Le
DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis
Hum. Mol. Genet.,
July 1, 2000;
9(11):
1671 - 1679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Schneider, E. Hilgenfeld, D. Schwabe, W. Behnisch, A. Zoubek, R. Wessalowski, and U. Gobel
Acute Myelogenous Leukemia After Treatment for Malignant Germ Cell Tumors in Children
J. Clin. Oncol.,
October 1, 1999;
17(10):
3226 - 3233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang, P. Strissel, R. Strick, J. Chen, G. Nucifora, M. M. Le Beau, R. A. Larson, and J. D. Rowley
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia
PNAS,
March 5, 2002;
99(5):
3070 - 3075.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Strick, P. L. Strissel, S. Borgers, S. L. Smith, and J. D. Rowley
From the Cover: Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
PNAS,
April 25, 2000;
97(9):
4790 - 4795.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
